Copyright
        ©The Author(s) 2017.
    
    
        World J Stem Cells. Dec 26, 2017; 9(12): 219-226
Published online Dec 26, 2017. doi: 10.4252/wjsc.v9.i12.219
Published online Dec 26, 2017. doi: 10.4252/wjsc.v9.i12.219
            Table 1 Criteria for severe aplastic anemia[1]
        
    | Peripheral blood, CBC findings | |
| Granulocytes | < 500/cu mm | 
| Platelets | < 20000/cu mm | 
| Reticulocytes | < 1% | 
| Bone marrow biopsy findings | |
| Hypoplasia | < 25% of normal cellularity | 
| 25%-50% of normal cellularity with < 30% hematopoietic cells | 
            Table 2 Summary of the clinical uses of mesenchymal stem cells in aplastic anemia
        
    | Treatment | Intervention | Goal (s) of therapy | Outcome | 
| MSC as adjunct to HCT | MSCs given in conjunction with hematopoietic stem cell transplantation | To prevent graft failure or shorten time to engraftment | Improved donor engraftment | 
| MSC as monotherapy | MSCs given alone | For primary treatment of AA | Partial response in some patients | 
- Citation: Broglie L, Margolis D, Medin JA. Yin and Yang of mesenchymal stem cells and aplastic anemia. World J Stem Cells 2017; 9(12): 219-226
- URL: https://www.wjgnet.com/1948-0210/full/v9/i12/219.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v9.i12.219

 
         
                         
                 
                 
                 
                 
                 
                         
                         
                        